Human papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil

BMC Cancer

Cristina Mendes de Oliveira³  José Humberto Tavares Guerreiro Fregnani⁴  Jesus Paula Carvalho¹  Adhemar Longatto-Filho⁵  José Eduardo Levi² 

[1] Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina, Universidade de São Paulo, Paulo, São Paulo, Brazil

[2] Instituto Nacional de Ciência e Tecnologia do HPV (INCT-HPV), Paulo, São Paulo, Brazil

[3] Laboratório de Virologia, Instituto de Medicina Tropical, Universidade de São, Paulo, São Paulo, Brazil

[4] Núcleo de Apoio ao Pesquisador do Hospital de Câncer de Barretos – Fundação Pio XII, Barretos, São Paulo, Brazil

[5] Laboratório de Investigação Médica (LIM) 14, Faculdade de Medicina, Universidade de São Paulo, Paulo, Brazil

关键词: Brazil;    Invasive cervical cancer (ICC);    Human Papillomavirus (HPV);   

Others  :  1079633
DOI  :  10.1186/1471-2407-13-357

 received in 2012-12-18, accepted in 2013-07-22,  发布年份 2013

【 摘 要 】

Background

Invasive cervical cancer is the second most common malignant tumor affecting Brazilian women. Knowledge on Human Papillomavirus (HPV) genotypes in invasive cervical cancer cases is crucial to guide the introduction and further evaluate the impact of new preventive strategies based on HPV. We aimed to provide updated comprehensive data about the HPV types’ distribution in patients with invasive cervical cancer.

Methods

Fresh tumor tissue samples of histologically confirmed invasive cervical cancer were collected from 175 women attending two cancer reference hospitals from São Paulo State: ICESP and Hospital de Câncer de Barretos. HPV detection and genotyping were performed by the Linear Array HPV Genotyping Test (Roche Molecular Diagnostics, Pleasanton,USA).

Results

170 out of 172 valid samples (99%) were HPV DNA positive. The most frequent types were HPV16 (77.6%), HPV18 (12.3%), HPV31 (8.8%), HPV33 (7.1%) and HPV35 (5.9%). Most infections (75%) were caused by individual HPV types. Women with adenocarcinoma were not younger than those with squamous cell carcinoma, as well, as women infected with HPV33 were older than those infected by other HPV types. Some differences between results obtained in the two hospitals were observed: higher overall prevalence of HPV16, absence of single infection by HPV31 and HPV45 was verified in HC-Barretos in comparison to ICESP patients.

Conclusions

To our knowledge, this is one of the largest studies made with fresh tumor tissues of invasive cervical cancer cases in Brazil. This study depicted a distinct HPV genotype distribution between two centers that may reflect the local epidemiology of HPV transmission among these populations. Due to the impact of these findings on cervical cancer preventive strategies, extension of this investigation to routine screening populations is warranted.

【 授权许可】

   
2013 de Oliveira et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase n .10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr webcite
• [2]INCA: Estimativa 2012 – Incidência de Câncer no Brasil. Rio de Janeiro: Ministério da Saúde; 2011.
• [3]Bosch FX, Lorincz A, Muñoz N, Meijer CJL, Shah KV: The causal relation between human papilomavírus and cervical cancer. J Clin Pathol 2002, 55:244-265.
• [4]De Villiers EM, Fauquet C, Broker TR, Bernard HU, Hausen H: Classification of papillomaviruses. Virology 2004, 324:17-27.
• [5]Bernard HU, Burk RD, Chen Z, Van Doorslaer K, Hausen H, De Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
• [6]Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM: Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med 2003, 348:518-527.
• [7]Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group: A review of human carcinogens-part B: biological agents. Lancet Oncol 2009, 10:321-322.
• [8]Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer DJLM, Muñoz N: Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
• [9]Schiffman M, Kjaer SK: Natural history of anogenital human papilomavírus infection and neoplasia. J Natl Cancer Inst Monogr 2003, 31:14-19.
• [10]Schiller JT, Castellsagué X, Villa LL, Hildesheim A: An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008, 26(Suppl 10):K53-K61.
• [11]De Sanjosé S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, De Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti AS, Kasamatsu TE, Iljazovic E, Odida M, Prado R, Seoud M, Usubutun MGA, Jain A, Suarez GAH, Lombardi LE, Banjo A, Menéndez C, et al.: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
• [12]Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM: Human Papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128:927-935.
• [13]Eluf-Neto J, Booth M, Muñoz N, Bosch FX, Meijer CJLM, Walboomers JMM: Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994, 69:114-119.
• [14]Noronha V, Mello W, Villa L, Brito A, Macedo R, Bisi F, Mota R, Sassamoto K, Monteiro T, Linhares A: Papilomavírus humano associado a lesões de cérvice uterina. Rev Soc Bras Med Trop 1999, 32:235-240.
• [15]Lorenzato F, Ho L, Terry G, Singer A, Santos LC, Batista RL, Lubambo T: The use of human papillomavirus typing in detection of cervical neoplasia in Recife (Brazil). Int J Gyn Cancer 2000, 10:143-150.
• [16]Fernandes JV, Meissner RV, Carvvalho MGF, Fernandes TAAM, Azevedo PRM, Sobrinho SJ, Prado JCM, Villa LL: Prevalence of human papillomavirus in archival samples obtained from patients with cervical pre-malignant and malignant lesions from Northeast Brazil. BMC Res Notes 2010, 3:96. BioMed Central Full Text
• [17]Estimativas de População – IBGE. http://www.ibge.gov.br webcite
• [18]FIGO: The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol 2009, 115:325-328.
• [19]Rabelo-Santos SH, Zeferino L, Villa LL, Sobrinho JP, Amaral RG, Magalhães AV: Human Papillomavirus Prevalence among Women with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer from Goiânia, Brazil. Mem Inst Oswaldo Cruz 2003, 98:181-184.
• [20]Bosch FX, Manos MM, Muñoz N, Sherman M, Jansesn AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV, International Biological Study on Cervical Cancer (IBSCC) Study Group: Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective. J Natl Cancer Inst 1995, 87:796-802.
• [21]Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007, 121:621-632.
• [22]Kasamatsu E, Cubilla AL, Alemany L, Chaux A, Tous S, Mendoza L, Paez M, Klaustermeier JE, Quint W, Lloveras B, De Sanjosé S, Muñoz N, Bosch FX: Type-Specific Human Papillomavirus Distribution in Invasive Cervical Carcinomas in Paraguay. A Study of 432 Cases. J Med Virol 2012, 84:1628-1635.
• [23]Greer CE, Lund JK, Manos MM: PCR Amplification from Paraffin-embedded Tissues: Recommendations on Fixatives for Long-term Storage and Prospective Studies. Genome Res 1991, 1:46-50.
• [24]Levi JE, Rahal P, Sarkis AS, Villa L: Human papillomavirus DNA and p53 status in penile carcinomas. Int J Cancer 1998, 76:779-783.
• [25]Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C: Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J Virol Methods 2009, 156:77-83.
• [26]Campbell CMP, Curado MP, Harlow SD, Soliman AS: Regional variation in histopathology-specific incidence of invasive cervical cancer among Peruvian women. Int J Gyn Obst 2012, 116:47-51.
• [27]Castellsagué X, Díaz M, De Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders JF, Meijer CJLM, Bosch FX: Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactores: Implications for Screening and Prevention. J Natl Cancer Inst 2006, 98:303-315.
• [28]Oliveira CM, Aguiar LS, Genta MLDN, Alves VAF, Levi JE: HPV-11 associated metastatic cervical cancer. Gynecol Oncol Reports 2012, 2:18-19.
• [29]Vinokurova S, Wwntzensen N, Kraus I, Kales R, Driesch C, Melssheimer P, Kisseljov F, Dürst M, Schneider A, Von Knebel Doeberitz M: Type-dependent integration frequency of human papillomavirus genome in cervical lesions. Cancer Res 2008, 68:307-313.